Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Rhea-AI Summary

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will report Q4 and year-end 2023 financial results on March 26, 2024. The company focuses on developing a therapeutic for Alzheimer's disease targeting toxic soluble amyloid beta oligomers.

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2023 financial results on Tuesday, March 26, 2024. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.

To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance. 

The webcast audio will be available via this link. 

An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.

About Acumen Pharmaceuticals, Inc.

Acumen, headquartered in Charlottesville, VA, with additional offices in Indianapolis, IN and Newton, MA, is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, following positive results in INTERCEPT-AD, a Phase 1 clinical trial involving early Alzheimer’s disease patients. For more information, visit www.acumenpharm.com.

Investors:
Alex Braun
abraun@acumenpharm.com

Media: 
AcumenPR@westwicke.com 

FAQ

When will Acumen Pharmaceuticals, Inc. (ABOS) report its Q4 and year-end 2023 financial results?

Acumen Pharmaceuticals, Inc. (ABOS) will report its Q4 and year-end 2023 financial results on March 26, 2024.

What is the focus of Acumen Pharmaceuticals, Inc. (ABOS) in terms of drug development?

Acumen Pharmaceuticals, Inc. (ABOS) focuses on developing a therapeutic targeting toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease.

How can one participate in the live conference call hosted by Acumen Pharmaceuticals, Inc. (ABOS)?

To participate in the live conference call hosted by Acumen Pharmaceuticals, Inc. (ABOS), one needs to register using the provided link and will be informed of the dial-in numbers including PIN.

Where can one find the archived version of the webcast by Acumen Pharmaceuticals, Inc. (ABOS)?

The archived version of the webcast by Acumen Pharmaceuticals, Inc. (ABOS) will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.